Main clinical studies of Bruton’s tyrosine kinase inhibitors (BTKis) (notice n° 174748)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 00817cam a2200157 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112040004.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Ysebaert, Loïc |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Main clinical studies of Bruton’s tyrosine kinase inhibitors (BTKis) |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 86 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Quality of life evaluation is crucial in therapeutic trials in hematology, but is not yet recognized as the only true patient-centered primary endpoint. For chronic lymphocytic leukemia patients, how can we move beyond focusing solely on progression-free survival to truly consider overall survival with good quality of life? |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 30 | Special Issue 1 | 2024-06-02 | p. 44-46 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-hematologie-2024-Supp1-page-44?lang=en">https://shs.cairn.info/journal-hematologie-2024-Supp1-page-44?lang=en</a> |
Pas d'exemplaire disponible.
Réseaux sociaux